These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 3914816)
81. Stimulation of (Pro-)insulin biosynthesis and release by gastric inhibitory polypeptide in isolated islets of rat pancreas. Schäfer R; Schatz H Acta Endocrinol (Copenh); 1979 Jul; 91(3):493-500. PubMed ID: 382725 [TBL] [Abstract][Full Text] [Related]
82. The effects of porcine GIP on insulin secretion and glucose clearance in the pig. Wolffbrandt KH; Damm Jørgensen K; Moody AJ; Pedersen PC Horm Metab Res; 1986 Mar; 18(3):159-62. PubMed ID: 3516832 [TBL] [Abstract][Full Text] [Related]
83. Assessment of the effects of insulin secretagogues in humans. Wallace TM; Matthews DR Diabetes Obes Metab; 2000 Oct; 2(5):271-83. PubMed ID: 11225742 [No Abstract] [Full Text] [Related]
84. The clinical utility of C-peptide measurement in the care of patients with diabetes. Jones AG; Hattersley AT Diabet Med; 2013 Jul; 30(7):803-17. PubMed ID: 23413806 [TBL] [Abstract][Full Text] [Related]
85. Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trials. Greenbaum CJ Clin Immunol; 2002 Aug; 104(2):97-104. PubMed ID: 12165270 [TBL] [Abstract][Full Text] [Related]
86. Effect of cyclosporin A on B-cell loss in type 1 (insulin-dependent) diabetes mellitus. Vague P; Vialettes B; Picq R; Dol S; Lassmann-Vague V Diabetologia; 1989 Dec; 32(12):887. PubMed ID: 2693167 [No Abstract] [Full Text] [Related]
87. Pancreatic elastase-1 in stools, a marker of exocrine pancreas function, correlates with both residual beta-cell secretion and metabolic control in type 1 diabetic subjects. Cavalot F; Bonomo K; Perna P; Bacillo E; Salacone P; Gallo M; Mattiello L; Trovati M; Gaia E Diabetes Care; 2004 Aug; 27(8):2052-4. PubMed ID: 15277440 [No Abstract] [Full Text] [Related]
89. Influence of ciamexon on blood glucose and insulin requirement in newly manifested type I diabetics. Results of a pilot study. Hogan M; Beyer J; Stuermer W; Weber P; Schrezenmeier J Arzneimittelforschung; 1988 Aug; 38(8):1185-9. PubMed ID: 3058137 [TBL] [Abstract][Full Text] [Related]
90. Tirzepatide: a new low for bodyweight and blood glucose. Bailey CJ Lancet Diabetes Endocrinol; 2021 Oct; 9(10):646-648. PubMed ID: 34419226 [No Abstract] [Full Text] [Related]
91. Gluco-lipotoxicity of the pancreatic beta cell. Poitout V; Briaud I; Kelpe C; Hagman D Ann Endocrinol (Paris); 2004 Feb; 65(1):37-41. PubMed ID: 15122090 [No Abstract] [Full Text] [Related]
92. Type of diabetes mellitus: Does it matter to the clinician? Hoogwerf BJ Cleve Clin J Med; 2020 Feb; 87(2):100-108. PubMed ID: 32015063 [TBL] [Abstract][Full Text] [Related]
93. Evaluation of B-cell function in diabetics by C-peptide determination in basal and postprandial urine. Fernandez-Castañer M; Rosel P; Ricart W; Montaña E; Gomez JM; Navarro MA; Soler Ramon J Diabete Metab; 1987; 13(5):538-42. PubMed ID: 3322892 [TBL] [Abstract][Full Text] [Related]